All data are reported as mean ± SEM and were analyzed using one-way between subjects analysis of variance (ANOVA), with the exception of the antagonist studies, which were analyzed using two-way factorial ANOVA, with antagonist and enzyme inhibitor as the factors. Post hoc comparisons of dose-response data used Dunnett's test to compare each dose to vehicle. Planned comparisons between rimonabant and vehicle were made using T tests. Immobility data were analyzed using repeated measures ANOVA, with time as the within-subjects variable. Differences were considered statistically significant at p < 0.05.
